A citation-based method for searching scientific literature

Alice B Gottlieb, Jashin J Wu, Christopher E M Griffiths, Kwaku Marfo, Elisa Muscianisi, Xiangyi Meng, Jennifer Frueh, Mark Lebwohl. J Dermatolog Treat 2022
Times Cited: 3







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
R Bissonnette, T Luger, D Thaçi, D Toth, A Lacombe, S Xia, R Mazur, M Patekar, P Charef, M Milutinovic,[...]. J Eur Acad Dermatol Venereol 2018
123
66

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
A Deodhar, P J Mease, I B McInnes, X Baraliakos, K Reich, A Blauvelt, C Leonardi, B Porter, A Das Gupta, A Widmer,[...]. Arthritis Res Ther 2019
148
66

European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
A Nast, P Gisondi, A D Ormerod, P Saiag, C Smith, P I Spuls, P Arenberger, H Bachelez, J Barker, E Dauden,[...]. J Eur Acad Dermatol Venereol 2015
282
66

Clinical improvement in psoriasis with specific targeting of interleukin-23.
Tamara Kopp, Elisabeth Riedl, Christine Bangert, Edward P Bowman, Elli Greisenegger, Ann Horowitz, Harald Kittler, Wendy M Blumenschein, Terrill K McClanahan, Thomas Marbury,[...]. Nature 2015
153
33

Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
K Reich, R B Warren, L Iversen, L Puig, I Pau-Charles, A Igarashi, M Ohtsuki, M Falqués, M Harmut, S Rozzo,[...]. Br J Dermatol 2020
60
33

Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Boni Elewski, Alan Menter, Jeffrey Crowley, Stephen Tyring, Yang Zhao, Simon Lowry, Stephen Rozzo, Alan M Mendelsohn, Jeffrey Parno, Kenneth Gordon. J Dermatolog Treat 2020
8
33

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
K Papp, D Thaçi, K Reich, E Riedl, R G Langley, J G Krueger, A B Gottlieb, H Nakagawa, E P Bowman, A Mehta,[...]. Br J Dermatol 2015
187
33

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis.
Jon T Giles, Alexis Ogdie, Juan J Gomez Reino, Philip Helliwell, Rebecca Germino, Lori Stockert, Pamela Young, Wael Joseph, Rajiv Mundayat, Daniela Graham,[...]. RMD Open 2021
11
33

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Kristian Reich, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, Nicole Cichanowitz, Qing Li,[...]. Lancet 2017
302
33

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
A Blauvelt, J C Prinz, A B Gottlieb, K Kingo, H Sofen, M Ruer-Mulard, V Singh, R Pathan, C Papavassilis, S Cooper. Br J Dermatol 2015
233
33

Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
33

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE).
Ulrich Mrowietz, Craig L Leonardi, Giampiero Girolomoni, Darryl Toth, Akimichi Morita, Shyamal A Balki, Jacek C Szepietowski, Pascaline Regnault, Helen Thurston, Charis Papavassilis. J Am Acad Dermatol 2015
142
33

Moderate and severe plaque psoriasis: cost-of-illness study in Italy.
Gl Colombo, Gf Altomare, K Peris, P Martini, G Quarta, M Congedo, A Costanzo, A Di Cesare, E Lapucci, S Chimenti. Ther Clin Risk Manag 2008
53
33


The Role of IL-17 in the Pathogenesis and Treatment of Psoriasis.
Joshua A Zeichner, April Armstrong. J Clin Aesthet Dermatol 2016
23
33

Uncovering the unmet needs among psoriasis patients in the Asia-Pacific region.
Yayoi Tada, Seong Jin Jo, Yu-Huei Huang, Bryan Wahking, Bong Young Lee, Regina Gowindah, Pablo Fernández-Peñas. J Dermatol 2021
2
50

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
Alan Menter, Joel M Gelfand, Cody Connor, April W Armstrong, Kelly M Cordoro, Dawn M R Davis, Boni E Elewski, Kenneth B Gordon, Alice B Gottlieb, Daniel H Kaplan,[...]. J Am Acad Dermatol 2020
92
33

Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
R Bissonnette, T Luger, D Thaçi, D Toth, I Messina, R You, A Guana, T Fox, C Papavassilis, I Gilloteau,[...]. Br J Dermatol 2017
41
33

Putting together the psoriasis puzzle: an update on developing targeted therapies.
Leanne M Johnson-Huang, Michelle A Lowes, James G Krueger. Dis Model Mech 2012
80
33

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi,[...]. Cochrane Database Syst Rev 2017
153
33


Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies.
M Augustin, D Jullien, A Martin, C Peralta. J Eur Acad Dermatol Venereol 2020
32
33

Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial.
J-P Lacour, C Paul, S Jazayeri, P Papanastasiou, C Xu, J Nyirady, T Fox, C Papavassilis. J Eur Acad Dermatol Venereol 2017
35
33

Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study.
D A Springate, R Parisi, E Kontopantelis, D Reeves, C E M Griffiths, D M Ashcroft. Br J Dermatol 2017
113
33

Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.
Alice B Gottlieb, Andrew Blauvelt, Jörg C Prinz, Philemon Papanastasiou, Rashidkhan Pathan, Judit Nyirady, Todd Fox, Charis Papavassilis. J Drugs Dermatol 2016
21
33

European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
A Nast, P I Spuls, G van der Kraaij, P Gisondi, C Paul, A D Ormerod, P Saiag, C H Smith, E Dauden, E M de Jong,[...]. J Eur Acad Dermatol Venereol 2017
85
33

Global epidemiology of psoriasis: a systematic review of incidence and prevalence.
Rosa Parisi, Deborah P M Symmons, Christopher E M Griffiths, Darren M Ashcroft. J Invest Dermatol 2013
33

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Dominique Baeten, Joachim Sieper, Jürgen Braun, Xenofon Baraliakos, Maxime Dougados, Paul Emery, Atul Deodhar, Brian Porter, Ruvie Martin, Mats Andersson,[...]. N Engl J Med 2015
583
33

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Iain B McInnes, Philip J Mease, Bruce Kirkham, Arthur Kavanaugh, Christopher T Ritchlin, Proton Rahman, Désirée van der Heijde, Robert Landewé, Philip G Conaghan, Alice B Gottlieb,[...]. Lancet 2015
530
33

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.
Boni E Elewski, Lluís Puig, Margaret Mordin, Isabelle Gilloteau, Bintu Sherif, Todd Fox, Ari Gnanasakthy, Charis Papavassilis, Bruce E Strober. J Dermatolog Treat 2017
31
33

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
C Paul, J-P Lacour, L Tedremets, K Kreutzer, S Jazayeri, S Adams, C Guindon, R You, C Papavassilis. J Eur Acad Dermatol Venereol 2015
215
33

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, Ruquan You,[...]. J Am Acad Dermatol 2015
369
33

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Alan Menter, Bruce E Strober, Daniel H Kaplan, Dario Kivelevitch, Elizabeth Farley Prater, Benjamin Stoff, April W Armstrong, Cody Connor, Kelly M Cordoro, Dawn M R Davis,[...]. J Am Acad Dermatol 2019
303
33

National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.
Rosa Parisi, Ireny Y K Iskandar, Evangelos Kontopantelis, Matthias Augustin, Christopher E M Griffiths, Darren M Ashcroft. BMJ 2020
184
33

IL-17-high asthma with features of a psoriasis immunophenotype.
Jörgen Östling, Marleen van Geest, James P R Schofield, Zala Jevnikar, Susan Wilson, Jonathan Ward, Rene Lutter, Dominick E Shaw, Per S Bakke, Massimo Caruso,[...]. J Allergy Clin Immunol 2019
52
33

Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses.
Lisa C Zaba, Irma Cardinale, Patricia Gilleaudeau, Mary Sullivan-Whalen, Mayte Suárez-Fariñas, Judilyn Fuentes-Duculan, Inna Novitskaya, Artemis Khatcherian, Mark J Bluth, Michelle A Lowes,[...]. J Exp Med 2007
491
33

New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study.
Jean-Guillaume Letarouilly, Thao Pham, Adeline Pierache, Émilie Acquacalda, Béatrice Banneville, Sébastien Barbarot, Pauline Baudart, Élodie Bauer, Pascal Claudepierre, Arnaud Constantin,[...]. Rheumatology (Oxford) 2022
1
100

Failure of Biologic Therapy in Psoriasis.
Rocío Cardona, Natalia M Pelet Del Toro, Eduardo Michelen-Gómez, Gabriel E Arias-Berrios, Rafael F Martín-García. P R Health Sci J 2021
1
100

A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.
U Mrowietz, E M G J de Jong, K Kragballe, R Langley, A Nast, L Puig, K Reich, J Schmitt, R B Warren. J Eur Acad Dermatol Venereol 2014
96
33

Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis.
P Gisondi, G Altomare, F Ayala, F Bardazzi, L Bianchi, A Chiricozzi, A Costanzo, A Conti, P Dapavo, C De Simone,[...]. J Eur Acad Dermatol Venereol 2017
95
33

Epicardial adipose tissue volume is greater in men with severe psoriasis, implying an increased cardiovascular disease risk: A cross-sectional study.
Charles N Ellis, Stephen J Neville, Mohamed Sayyouh, James T Elder, Rajan P Nair, Johann E Gudjonsson, Tianwen Ma, Ella A Kazerooni, Melvyn Rubenfire, Prachi P Agarwal. J Am Acad Dermatol 2022
4
33

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents.
Giovanni Damiani, Chiara Franchi, Paolo Pigatto, Andrea Altomare, Alessia Pacifico, Stephen Petrou, Sebastiano Leone, Maria Caterina Pace, Marco Fiore. World J Hepatol 2018
24
33

Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches.
Anna Campanati, Andrea Marani, Emanuela Martina, Federico Diotallevi, Giulia Radi, Annamaria Offidani. Biomedicines 2021
12
33

Cytokine alterations in psoriasis: an updated review.
Homa Seyedmirzaei, Nima Rezaei. Expert Rev Clin Immunol 2021
2
50

PRURITUS CHARACTERISTICS IN A LARGE ITALIAN COHORT OF PSORIATIC PATIENTS.
Giovanni Damiani, Simone Cazzaniga, Rosalynn Rz Conic, Luigi Naldi. J Eur Acad Dermatol Venereol 2019
24
33

Apremilast and Secukinumab Combined Therapy in a Patient With Recalcitrant Plaque Psoriasis.
Brooke E Rothstein, Brianna McQuade, Jacqueline E Greb, Ari M Goldminz, Alice B Gottlieb. J Drugs Dermatol 2016
14
33

HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
Nick Dand, Michael Duckworth, David Baudry, Alice Russell, Charles J Curtis, Sang Hyuck Lee, Ian Evans, Kayleigh J Mason, Ali Alsharqi, Gabrielle Becher,[...]. J Allergy Clin Immunol 2019
72
33


Reliability and validity of the Psoriasis Itch Visual Analog Scale in psoriasis vulgaris.
Claus Bang Pedersen, Colleen A McHorney, Lotte Seiding Larsen, Katja Wendicke Lophaven, Anders Holmen Moeller, Matthew Reaney. J Dermatolog Treat 2017
12
33

Optimizing Secukinumab Treatment in Psoriasis with Concomitant Methotrexate Administration: Minireview and A Case Report.
Dimitra Kostaki, Emilia Aquila, Laura Macaluso, Carlo Mattozzi, Antonio Giovanni Richetta. Case Rep Dermatol 2019
5
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.